California State Teachers Retirement System (CalSTRS)’s Nuvectis Pharma NVCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.47K Sell
837
-116
-12% -$994 ﹤0.01% 2812
2025
Q4
$7.2K Buy
953
+149
+19% +$971 ﹤0.01% 2885
2025
Q3
$4.84K Buy
804
+1
+0.1% +$7 ﹤0.01% 2984
2025
Q2
$6K Buy
+803
New +$7.28K ﹤0.01% 2882
2024
Q2
Sell
-747
Closed -$6.13K 3155
2024
Q1
$6.13K Sell
747
-477
-39% -$4.06K ﹤0.01% 2984
2023
Q4
$10.2K Sell
1,224
-417
-25% -$3.72K ﹤0.01% 2999
2023
Q3
$21.2K Sell
1,641
-638
-28% -$9.24K ﹤0.01% 2975
2023
Q2
$36.4K Buy
+2,279
New +$36.4K ﹤0.01% 3007

Other funds holding NVCT

California State Teachers Retirement System (CalSTRS)'s NVCT Position: Q1 2026 in Review

California State Teachers Retirement System (CalSTRS) reduced its Nuvectis Pharma (NVCT) stake by 12% in Q1 2026, selling an estimated $994 and leaving 837 shares worth $6.47K. The position accounts for ﹤0.01% of the portfolio, ranked #2812.

California State Teachers Retirement System (CalSTRS) first reported a position in NVCT in Q2 2023 and has held it in 8 quarters since. The position peaked at $36.4K in Q2 2023. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • California State Teachers Retirement System (CalSTRS) held 837 shares of Nuvectis Pharma worth $6.47K as of Q1 2026.
  • California State Teachers Retirement System (CalSTRS) sold 116 Nuvectis Pharma shares in Q1 2026, an estimated $994.
  • Nuvectis Pharma made up ﹤0.01% of California State Teachers Retirement System (CalSTRS)'s portfolio in Q1 2026, its #2812 holding.
  • California State Teachers Retirement System (CalSTRS) first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 8 quarters since.
  • California State Teachers Retirement System (CalSTRS)'s Nuvectis Pharma position peaked at $36.4K in Q2 2023.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on California State Teachers Retirement System (CalSTRS)'s 13F filing for Q1 2026, filed 18 May 2026.